-+ 0.00%
-+ 0.00%
-+ 0.00%

Sarepta to present 3-year EMBARK trial data for Elevidys gene therapy in Duchenne muscular dystrophy at WMS 2026

PUBT·09/25/2026 12:31:53
Listen to the news
Sarepta to present 3-year EMBARK trial data for Elevidys gene therapy in Duchenne muscular dystrophy at WMS 2026
  • Sarepta Therapeutics outlined new Duchenne muscular dystrophy data slated for presentation at the World Muscle Society congress Sept. 29-Oct. 3.
  • A late-breaking poster will cover efficacy and safety outcomes for its gene therapy in older ambulatory patients treated at ages 8-12.
  • Additional presentations will update longer-term outcomes from the EMBARK study, extending follow-up to three years post-infusion.
  • Separate posters will summarize pooled safety across Phase 1-3 trials, alongside Phase 3 results for golodirsen and casimersen versus placebo.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260925573264) on September 25, 2026, and is solely responsible for the information contained therein.